Romark Institute for Medical Research

Romark is a biopharmaceutical company specializing in the discovery and development of small molecule drugs for infectious diseases. The company's flagship product, Alinia (nitazoxanide), is an FDA-approved treatment for intestinal parasitic infections and serves as the foundation for their thiazolide platform. Romark is actively advancing clinical trials for broad-spectrum antiviral applications of nitazoxanide, targeting respiratory infections such as influenza and COVID-19. Based in Tampa, Florida, the company operates as a vertically integrated entity, managing research, clinical development, and commercial operations. Their mission focuses on addressing significant unmet needs in global health, particularly in the realm of viral and parasitic pathogens.